Stock Taper 
| DATE | TYPE | RATIO |
|---|---|---|
| 2025-12-01 | Reverse | 1:25 |
| 2024-03-22 | Reverse | 1:15 |
| 2021-02-01 | Reverse | 1:6 |
Moleculin Biotech, a Houston-based clinical-stage company, develops drug candidates like Annamycin and WP1066 targeting resistant tumors, viruses, and cancers, with ongoing Phase 1/2 trials for AML, brain tumors, and COVID-19.
Annamycin, Moleculin Biotech’s lead clinical-stage drug, is a next-generation anthracycline in Phase 3 trials for relapsed/refractory AML and STS lung metastases.
Moleculin Biotech announced positive results from the Emory University physician-sponsored Phase 1 clinical trial of WP1066 for the treatment of pediatric recurrent malignant brain tumors. The study, conducted at the Aflac Cancer and Blood Disorders Center at Children's Healthcare of Atlanta, demonstrated that WP1066 induces anti-tumor immune responses and was found to be well-tolerated. This was a significant development as STAT3, which WP1066 inhibits, is considered critical to certain childhood brain tumors.
Moleculin Biotech implemented a 1-for-25 reverse stock split to increase its stock price and regain compliance with the Nasdaq's minimum bid price requirement. This move was a critical step to avoid delisting and maintain access to public capital markets, though it was met with a significant negative reaction from investors.
HOUSTON, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”) today announced that it will present at the upcoming 2026 Maxim Growth Summit in New York, NY. Details of the presentation are as follows:
Overall rating: B-
| PEER | PRICE | |
|---|---|---|
 APLM | $21.94 | COMPARE |
 CTXR | $0.51 | COMPARE |
 BLRX | $2.21 | COMPARE |
 ICU | $3.21 | COMPARE |
 AIMD | $1.22 | COMPARE |
 LNAI | $1.12 | COMPARE |
